Detection and quantification of Aβ−3–40 (APP669‐711) in cerebrospinal fluid
Open Access
- 4 January 2022
- journal article
- research article
- Published by Wiley in Journal of Neurochemistry
- Vol. 160 (5), 578-589
- https://doi.org/10.1111/jnc.15571
Abstract
Neurochemical biomarkers can support the diagnosis of Alzheimer’ disease and may facilitate clinical trials. In blood plasma, the ratio of the amyloid-β (Aβ) peptides Aβ−3–40/Aβ1–42 can predict cerebral amyloid-β pathology with high accuracy (Nakamura et al., 2018). Whether or not Aβ−3–40 (aka. amyloid precursor protein (APP) 669-711) is also present in cerebrospinal fluid (CSF) is not clear. Here, we investigated whether Aβ−3–40 can be detected in CSF and to what extent the CSF Aβ−3–40/Aβ42 ratio is able to differentiate between individuals with or without amyloid-β positron emission tomography (PET) evidence of brain amyloid. The occurrence of Aβ−3–40 in human CSF was assessed by immunoprecipitation followed by mass spectrometry. For quantifying the CSF concentrations of Aβ−3–40 in 23 amyloid PET-negative and 17 amyloid PET-positive subjects, we applied a sandwich-type immunoassay. Our findings provide clear evidence of the presence of Aβ−3–40 and Aβ−3–38 in human CSF. While there was no statistically significant difference in the CSF concentration of Aβ−3–40 between the two diagnostic groups, the CSF Aβ−3–40/Aβ42 ratio was increased in the amyloid PET-positive individuals. We conclude that Aβ−3–40 appears to be a regular constituent of CSF and may potentially serve to accentuate the selective decrease of CSF Aβ42 in Alzheimer’s disease.Keywords
This publication has 36 references indexed in Scilit:
- Analysis of Amino-Terminal Variants of Amyloid-β Peptides by Capillary Isoelectric Focusing ImmunoassayAnalytical Chemistry, 2013
- Aberrant Amyloid Precursor Protein (APP) Processing in Hereditary Forms of Alzheimer Disease Caused by APP Familial Alzheimer Disease Mutations Can Be Rescued by Mutations in the APP GxxxG MotifOnline Journal of Public Health Informatics, 2010
- Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascadeThe Lancet Neurology, 2010
- Early and Differential Diagnosis of Dementia and Mild Cognitive ImpairmentDementia and Geriatric Cognitive Disorders, 2009
- Characterization of Amyloid β Peptides in Cerebrospinal Fluid by an Automated Immunoprecipitation Procedure Followed by Mass SpectrometryJournal of Proteome Research, 2007
- Urea‐based two‐dimensional electrophoresis of beta‐amyloid peptides in human plasma: Evidence for novel Aβ speciesProteomics, 2007
- Intracellular Aβ and cognitive deficits precede β-amyloid deposition in transgenic arcAβ miceNeurobiology of Aging, 2007
- Determination of β-Amyloid Peptide Signatures in Cerebrospinal Fluid Using Immunoprecipitation-Mass SpectrometryJournal of Proteome Research, 2006
- The Arctic Alzheimer mutation facilitates early intraneuronal Aβ aggregation and senile plaque formation in transgenic miceNeurobiology of Aging, 2006
- Rapid Communication: Characterization of β‐Amyloid Peptide from Human Cerebrospinal FluidJournal of Neurochemistry, 1993